In response to T-cell receptor (TCR) triggering, quiescent CD8 + T lymphocytes transition to a proliferative effector state. During this response, memory CD8 + T lymphocytes form and can persist for the entire lifespan of the organism, mounting rapid recall responses, thereby providing long-term immunity. The metabolic programs of these different CD8 + T-lymphocyte states are distinct and important for function [1][2][3][4] . Effector CD8 + T lymphocytes generate most ATP and biomass through glycolysis 5 ; both naive and memory cells rely heavily on oxidative phosphorylation 6,7 . Various cytokines and transcription factors are important for the differentiation of CD8 + T lymphocytes, and it is evident that immunological memory is influenced by epigenetic mechanisms 8-12 .
The VHL-HIF-1α axis regulates 2HG production
To elucidate the metabolic effects of HIF-1α activation, we profiled the metabolome of CD8 + T lymphocytes with low (Vhl fl/fl ), or high (Vhl fl/fl dLck cre , denoted as Vhl −/− ) HIF signalling, and knockout of both Hif-1α and Vhl (Hif1a fl/fl Vhl fl/fl dLck cre , denoted as Hif1a −/− Vhl −/− ) to control for a specific contribution of HIF-1α 14 . Unsupervised clustering and principal component analysis (Fig. 1a, b ) separate Vhl −/− from Vhl fl/fl CD8 + T lymphocytes. Vhl −/− Hif1a −/− cluster with Vhl fl/fl , indicating that Hif-1α mediates significant metabolic changes following Vhl deletion. Glycolysis is important for sustaining effector function 1-3, 17 and these data indicate that Vhl suppresses glycolysis via inhibition of Hif-1α, (Extended Data Fig. 1a-c) .
Vhl loss suppresses late and increases early tricarboxylic acid (TCA) cycle intermediates (Extended Data Fig. 1a ). Notably, 2HG is significantly enriched in Vhl −/− CD8 + T lymphocytes ( Fig. 1c , Extended Data Fig. 1d ). Furthermore, increases in 2HG are dependent on Hif-1α when Vhl is deleted (Extended Data Fig. 1a ). This was validated using quantitative mass spectrometry in Vhl −/− and Vhl −/− Hif1a −/− CD8 + T lymphocytes ( Fig. 1d ), as well as in VHL-null cell lines, that express either HIF-1α (RCC4) or HIF-2α (786-O), reconstituted with VHL ( Fig. 1e , Extended Data Fig. 1e ). Deletion of Vhl in murine embryonic fibroblasts from Vhl fl/fl mice increases 2HG levels ( Fig. 1f , Extended Data Fig. 1f ). Hence, the VHL-HIF signalling axis regulates 2HG levels, and constitutive Hif-1α signalling underlies this effect in Vhlnull CD8 + T lymphocytes.
HIF-1α regulates S-2HG production
R-2HG production is increased by isocitrate dehydrogenase 1 and/or isocitrate dehydrogenase 2 mutations in different cancers [18] [19] [20] ; accumulation of the S-2HG enantiomer occurs in the context of hypoxia 21, 22 and mitochondrial dysfunction 23, 24 . We thus sought to determine 2HG levels in CD8 + T lymphocytes following activation. 2HG before activation and at sea-level oxygen is undetectable, whereas levels at the same oxygenation are elevated 2-4 days after TCR stimulation ( Fig. 2a ).When activated CD8 + T lymphocytes are exposed to 1% oxygen, the intracellular concentration of 2HG reaches millimolar levels (Fig. 2b, Extended Data Fig. 2a ) and is proportional to the degree of oxygenation (Fig. 2c ). We confirmed this using 1 HNMR spectroscopy (Extended Data Fig. 2b ). Given such high levels of 2HG, we sequenced 25 Idh1/2, to preclude the unlikely possibility that culturing primary murine CD8 + T lymphocytes in hypoxia gives rise to mutations known to cause R-2HG production in humans 18 ; we found no evidence for such mutations (Extended Data Fig. 3a-e ). Resolving the enantiomers of 2HG indicates that S-2HG constitutes the majority of the 2HG pool ( Fig. 2d ). Primary human CD8 + T lymphocytes also accumulate S-2HG in hypoxia ( Fig. 2e, f) , indicating that this is not limited to mouse lymphocytes.
We carried out deletion of loxP-flanked Hif1a or Hif2a (also known as Epas1) genes in CD8 + T lymphocytes, using dLck cre (ref. 26 ; Extended Data Fig. 2c ). 2HG accumulation is abolished in Hif1a fl/fl dLck cre (denoted as Hif1a −/− ), but not Hif2a fl/fl dLck cre (denoted as Hif2a −/− ) cells under hypoxia ( Fig. 2g, h ; Extended Data Fig. 2d , e), with no difference in viability (Extended Data Fig. 2f ). We next examined 2HG levels in vivo, in the spleens of mice. There is more R-2HG than S-2HG (Fig. 2i) ; furthermore, the levels of S-2HG are significantly decreased in spleens of Hif1a fl/fl dLck cre mice (Fig. 2i ). There is also a slight decrease in the levels of R-2HG (Fig. 2i ). 2HG is present in the urine of healthy individuals and is elevated in patients with 2HG acidurias 27 . Hif1a fl/fl dLck cre mice have lower levels of S-2HG in urine ( Fig. 2j) indicating that Hif-1α in the T-lymphocyte (CD4 + and CD8 + ) compartment makes a contri bution to S-2HG production in vivo. Activated Hif1a −/− CD8 + T lymphocytes in 21% oxygen have lower 2HG at extended time points (Extended Data Fig. 2g ), indicating a contribution of Hif-1α in non-hypoxic conditions also.
We next sought to determine the metabolic route by which Hif-1α promotes S-2HG production in CD8 + T lymphocytes. Transcriptionally, hypoxic CD8 + T lymphocytes show induction of glycolysis and suppression of the TCA cycle (Extended Data Fig. 2h ). Moreover, TCA cycle intermediates are decreased (Extended Data Fig. 2i ). Recent reports implicate lactate and malate dehydrogenases (Ldha and Mdh1/2) as enzymatic sources of S-2HG in hypoxia 21, 22 . In Hif1a −/− CD8 + T lymphocytes, the hypoxic expression of these enzymes suggests that Mdh1 and Mdh2 are unlikely to mediate the hypoxia-induced accumulation of S-2HG (Extended Data Fig. 2j ). Confirming this, knockdown of Mdh1 or Mdh2 does not decrease S-2HG in hypoxia (Extended Data Fig. 2k -m); knockdown of Mdh1 leads to marginal increases in S-2HG (Extended Data Fig. 2l ). Knockdown of Mdh1 or Mdh2 increases R-2HG levels (Extended Data Fig. 2l , m). Knockdown of Ldha (Extended Data Fig. 2k ) decreases S-2HG (Fig. 2k ), and also increases R-2HG levels in hypoxic CD8 + T lympho cytes (Extended Data Fig. 2n ). Overexpression of Ldha in hypoxic Hif1a −/− CD8 + T lymphocytes (Extended Data Fig. 2o ) rescues S-2HG production ( Fig. 2l ). Consistent with this, Ldha 
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expression in hypoxic CD8 + T lymphocytes is HIF-1α-dependent (Extended Data Fig. 2j ).
We next performed 13 C-labelling experiments and, in agreement with previous reports 21, 23 , uniformly labelled (U-) 13 C-glucose and U-13 C-glutamine tracing indicates that glutamine is the major source of 2HG, (Fig. 2m , Extended Data Fig. 4a -c). The m+5 isotopologue dominates, suggesting direct conversion of glutamine-derived 2-oxoglutarate to 2HG 21, 23 . Furthermore, the glutamate pool increases in hypoxic conditions (Extended Data Fig. 2p ) and in Vhl −/− CD8 + T lymphocytes (Extended Data Fig. 1a ) and depends on Hif-1α (Extended Data Fig. 2q ) but not Hif-2α (Extended Data Fig. 2r ). Inhibition of pyruvate dehydrogenase (Pdh) by pyruvate dehydrogenase kinases (Pdk), promotes glutaminolysis [28] [29] [30] . We reasoned that Pdk supports S-2HG production by diverting glutamine-derived 2-oxoglutarate to Ldha and, consistent with this, dichloroacetate (DCA) abrogates hypoxia-induced 2HG accumulation (Extended Data Fig. 2s -u). Pdk1 expression is impaired in hypoxic Hif1a −/− CD8 + T lymphocytes (Extended Data Fig. 2j ), as is phosphorylation of Pdh (Extended Data Fig. 2s ), and re-expression of Pdk1 in this context increases S-2HG in hypoxia ( Fig. 2l , Extended Data Fig. 2o ). Inhibition of Pdk activity also impedes hypoxia-induced increases in the glutamate pool (Extended Data Fig. 2v ). Hence, HIF-1α drives S-2HG production in hypoxic CD8 + T lymphocytes through the Pdk-Pdh signalling axis and Ldha induction (Extended Data Fig. 4a ).
S-2HG alters CD8 + T-cell differentiation
S-2HG inhibits 2-oxoglutarate-dependent dioxygenases 31, 32 . Consistent with this, Hif-1α is stabilized in normoxic (Extended Data Fig. 5a ) and hypoxic (Extended Data Fig. 5b ) CD8 + T lymphocytes by treatment with cell-permeable S-2HG, suggesting that S-2HG augments HIF signalling in normoxia and hypoxia. Additionally, there is increased phosphorylation of Pdh-E1α (Extended Data Fig. 5a , b), elevated glucose uptake, lactate secretion (Extended Data Fig. 5c ) and Vegfa production (Extended Data Fig. 5d ), indicating Hif-1αdependent effects. As Hif-1α supports effector functions in CD8 + T lymphocytes 13, 15 , we reasoned that S-2HG promotes effector differentiation through Hif-1α. However, unexpectedly, there is suppression of effector cytokine production (Extended Data Fig. 5e ) and decreased cytotoxicity (Extended Data Fig. 5f ). Furthermore, S-2HG restrains cell expansion (Extended Data Fig. 5g ) and there is a clear increase in apoptosis at doses greater than 300 μM (Extended Data Fig. 5h , i). Further characterization revealed decreased secretion of IFN-γ (Extended Data Fig. 5j ), yet elevated production of IL-2 ( Fig. 3a) , with increased viability in the absence of IL-2 supplementation (Extended Data Fig. 5k ). This possibly reflects an autocrine pro-survival effect. These effects are robustly mediated at the transcriptional level after prolonged treatment with S-2HG ( Fig. 3b , Extended Data Fig. 5l ) and are independent of HIF-1α ( Fig. 3a , Extended Data Fig. 5j , k).
We then characterized the phenotype of cells that had been treated with a prolonged course of S-2HG. There is increased expression of CD62L ( Fig. 3c , Extended Data Fig. 5m ) and this is reversible upon withdrawal of treatment (Extended Data Fig. 5n ).The effect does not occur when treating cells cultured in vehicle for 7 days (Extended Data Fig. 5n ), demonstrating that S-2HG treatment of newly activated cells maintains this phenotypic marker. Importantly, CD62L downregulation does not occur when Hif-1α is absent 15 , which masks the effect of S-2HG on CD62L following Hif-1α deletion (Extended Data Fig. 5o ). Hif-2α is dispensable for CD62L maintenance in response to S-2HG (Extended Data Fig. 5p ). With S-2HG, CD62L maintenance depends on the level of antigenic stimulation ( Fig. 3d ). Furthermore, S-2HG-treated cells express more CD127 (Fig. 3c ), CD44, 41BB, Eomes and less PD-1 in a Hif-1α-independent manner (Extended Data Fig. 5q ).
To determine the role of endogenously produced S-2HG, overexpression of L2hgdh (Extended Data Fig. 5r ), a dehydrogenase that oxidizes S-2HG, was performed. Overexpression of L2hgdh promotes the downregulation of CD62L in both 21% and 1% oxygen ( Fig. 3e ), indicating that endogenously produced S-2HG regulates CD62L expression. Furthermore, L2hgdh overexpression leads to an increase in the proportion of Klrg1 hi cells, which are decreased in the presence of exogenous S-2HG ( Fig. 3f ). Conversely, successful short hairpin RNA (shRNA)-mediated knockdown of L2hgdh by hairpin 3 (Extended Data Fig. 5s ) increases endogenous S-2HG levels ( Fig. 3g ), especially in 1% oxygen, promoting maintenance of CD62L ( Fig. 3h ). Knockdown of L2hgdh blocks loss of CD62L in response to low oxygen (Fig. 3h) . The same effect is seen with CD127 in low oxygen (Extended Data Fig. 5t ). These data demonstrate that L2hgdh activity regulates the expression of key phenotypic makers of CD8 + T lymphocytes, by controlling endo genous S-2HG levels. Transcriptionally, S-2HG treatment increases expression of Eomes, Ccr6, Bcl6, Sell (Cd62l) and Tcf7, 
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with repression of Prdm1, after 7 days (Extended Data Fig. 5u ). This transcriptional program is similar to gene expression changes in memory CD8 + T lymphocytes, suggesting that S-2HG treatment of CD8 + T lymphocytes ex vivo may enhance long-term persistence and survival in the context of adoptive cell transfer 33 .
We thus co-transferred CFSE-labelled vehicle and S-2HG treated CD45.1.1 or CD45.1.2 OT-I CD8 + T lymphocytes into lymphocytedepleted mice (Extended Data Fig. 6a ) to assess their capacity for homeostatic proliferation 34, 35 . S-2HG-treated cells display greater homeostatic proliferation ( Fig. 4a, b) , with more cells dividing more than 5 times ( Fig. 4c ).We then assessed the capacity of S-2HG treated cells to persist in lymphoreplete mice. Adoptively transferred ovalbumin-specific CD45.1 OT-I CD8 + T lymphocytes, pre-treated with S-2HG, show markedly enhanced persistence 30 days after transfer ( Fig. 4d ), expressing elevated CD44, CD127 and Bcl-2 levels relative to naive cells 36, 37 (Fig. 4e ). In response to vaccination with ovalbuminderived protein SIINFEKL-loaded dendritic cells, S-2HG-treated OT-I CD8 + T lymphocytes robustly recall ( Fig. 4f and Extended Data Fig. 6b, c) . Consistent with this, OT-I CD8 + T lymphocytes, pre-treated with S-2HG are more proficient at controlling tumour growth in vivo in both lymphocyte-depleted ( Fig. 4g ) and lymphoreplete ( Fig. 4h ) mice. These data demonstrate that S-2HG treatment ex vivo maintains cells in a state with increased proliferative and survival capacity, when transferred in vivo, that is otherwise decreased by effector differentiation.
S-2HG alters methylation in CD8 + T cells
Mechanistic target of rapamycin (mTOR) is a modifier of CD8 + T-lymphocyte differentiation; however, we do not observe mTOR inhibition 36, 38 at doses of S-2HG needed for this to occur (Extended Data Fig. 7 ). S-HG treatment ex vivo may be selecting cells that express higher levels of anti-apoptotic genes. Two critical anti-apoptotic genes implicated in CD8 + T-lymphocyte survival are Bcl-2 and Bcl-XL 39, 40 . These genes are not induced by S-2HG treatment (Extended Data Fig. 8a-d) . Moreover, overexpression of Bcl-2 or Bcl-XL (Extended Data Fig. 8e ) does not influence the expression of CD62L, CD44 or CD127 in the presence or absence of S-2HG (Extended Data Fig. 8f -i), indicating that S-2HG is exerting these phenotypic changes independently of Bcl-2 or Bcl-XL.
Inhibition of 2-oxoglutarate-dependent dioxygenases that deme thylate histones (Jumonji C containing proteins) or oxidise 5-methylcy tosine in DNA (Ten-eleven translocation (Tet) proteins) may mediate the effect of S-2HG 32, [41] [42] [43] . S-2HG alters global levels of various histone methylation marks (Extended Data Fig. 9a ); in particular, di-and tri-methylation on H3K27 are reciprocally altered, indicating inhibition of H3K27me3 demethylation ( Fig. 5a , b, Extended Data Fig. 9b ). The H3K27me2/3 demethylase Utx (also known as Kdm6a) is an important regulator of thymocyte differentiation 44 ; changes in H3K27me3 levels correlate with genes associated with regulation of CD8 + T lymphocyte differentiation 11 . Global levels of H3K27me3 in CD8 + T lymphocytes are reduced following activation, but remain high with S-2HG treatment in a HIF-1α-independent manner (Fig. 5c, Extended Data Fig. 9c ). Utx is induced following TCR stimulation (Extended Data Fig. 9d ) and inhibition of Utx reproduces the effect of S-2HG treatment on CD62L expression ( Fig. 5d , Extended Data Fig. 9e, f) . In vivo, levels 
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of H3K27me3 are highest in central memory (CD62L hi CD44 hi ) and naive (CD62L hi CD44 lo ) CD8 + T lymphocytes, relative to effectors (CD62L lo CD44 hi ) (Fig. 5e ). To determine whether histone methylation changes occur at the transcription start site (TSS) of CD62L with S-HG treatment, we performed chromatin immunoprecipitation (ChIP)-PCR for H3K27me3, H3K4me3 and RNA polymerase II (RNA Pol II), on naive and activated CD8 + T lymphocytes cultured with or without S-2HG (Fig. 5f, Extended Data Fig. 9g ). We could find no enrichment for H3K27me3 at or around the TSS. However, naive and S-2HGtreated CD8 + T lymphocytes have higher enrichment for H3K4me3 at the TSS that is reduced in vehicle-treated cells. Additionally, S-2HG treated CD8 + T lymphocytes have markedly higher RNA Pol II binding than both naive and vehicle-treated cells. Thus, S-2HG promotes CD62L transcription directly through enrichment of H3K4me3 at the TSS and indirectly through preservation of H3K27me3 elsewhere in the genome.
Total levels of 5-methylcytosine (5mC) in genomic DNA are largely unchanged by TCR triggering (Fig. 6a ). However, total levels of 5-hydroxymethylcytosine (5hmC) decrease following TCR triggering (Fig. 6a ). 5hmC removal in genomic DNA can occur through Tetmediated oxidation (active) as well as DNA replication (passive) 45, 46 . S-2HG treatment induces small changes in total 5hmC and 5mC in a time-dependent manner (Fig. 6b, c) ; at day 3, there are marginally higher levels of 5hmC (statistically non-significant) with no changes in 5mC (Fig. 6b, c) . This is probably due to decreased proliferation in the presence of S-2HG (Extended Data Fig. 5g ). Following sustained treatment, at days 7 and 9, cells have less 5hmC and more 5mC (Fig. 6b, c) . 5mC changes did not reach statistical significance at any time point; changes in 5hmC were statistically significant at day 7 only. Nonetheless, the changes at days 7 and 9 are consistent with inhibition of Tet proteins in the presence of sustained S-2HG treatment.
Tet2 regulates CD4 + T-lymphocyte function and is inhibited by 2HG 47, 48 . Knockdown of Tet2 recapitulates the effect of S-2HG on CD62L, indicating that Tet2 also contributes to CD8 + T-lymphocyte effector differentiation (Fig. 6d, Extended Data Fig. 10a ), implicating DNA demethylation as an added epigenetic modifier of CD8 + T-cell differentiation 12 . We performed both 5hmC and 5mC DNA immunoprecipitation (DIP)-PCR around the TSS of CD62L (Fig. 6e , Extended Data Fig. 10b ). Naive cells have the highest and lowest enrichment for 5hmC and 5mC respectively, whereas S-2HG-treated cells display the opposite pattern. Vehicle-treated cells have an intermediate level of these two marks.
Discussion
Our data support a model in which both Utx and Tet2 contribute to effector differentiation of CD8 + T lymphocytes in vitro. The activity of these epigenetic modifiers is altered by S-2HG in a fashion that inhibits effector differentiation.
TCR-triggering induced loss of 5hmC in genomic DNA, whereas 5mC levels were relatively stable (Fig. 6a ). 5hmC levels stabilized by four days after activation ( Fig. 6a ) and S-2HG treatment produced reciprocal changes in 5mC and 5hmC levels at later time points (Fig. 6b, c) . We investigated 5mC and 5hmC presence at and around the TSS of CD62L (Fig. 6e ). S-2HG treatment causes reciprocal 5mC increases and 5hmC decreases in this region consistent with inhibition of Tet proteins and transcriptional repression 47 , yet there is robust expression of CD62L with S-2HG treatment ( Fig. 3c -e, h, Extended Data Fig. 5m-p) . Inhibition of Tet2 maintains CD62L expression ( Fig. 6d , Extended Data Fig. 10a ), indicating that S-2HG-induced DNA methylation changes elsewhere in the genome may indirectly promote CD62L expression.
We also investigated H3K4me3 and H3K27me3 patterns at the TSS of CD62L (Fig. 5f ). S-2HG-treated and naive CD8 + T lymphocytes have high enrichment for the active H3K4me3 mark 49 at the TSS that is lost in vehicle-treated cells. In S-2HG-treated cells, this is accompanied by binding of RNA Pol II. Despite global increases in H3K27me3 with S-2HG (Fig. 5a-c) , the lack of H3K27me3 at the TSS of CD62L is not surprising, as this mark is associated with repression 49 . Nevertheless, inhibition of Utx promotes CD62L maintenance (Fig. 5d , Extended Data Fig. 9e, f) , indicating that H3K27me3 deposition at other genomic sites can indirectly promote CD62L expression. Owing to the relationship between histone methylation and other marks such as histone acetylation, modulation of the latter may have similar effects to those seen with S-2HG treatment 50 .
Adoptively transferred cells treated with S-2HG ex vivo have an increased capacity to proliferate and persist in vivo, with enhanced anti-tumour efficacy (Fig. 4) , demonstrating a new strategy to improve persistence of adoptive cell therapies for cancer. The data presented uncover a metabolic-epigenetic axis that controls aspects of T-cell fate. Factors regulating endogenous S-2HG levels, such as HIF signalling, TCR triggering, L2hdgh activity and potentially others, can alter the differentiation of CD8 + T lymphocytes and thus shape the immune response.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
Data Availability
The data that support the findings are available from the corres ponding author upon reasonable request. 
Extended Data Figure 2 | See next page for caption.
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Extended Data Figure 2 | Hif-1α-dependent metabolic alterations underlie S-2HG production in CD8 + T lymphocytes. a, Example calculation of intracellular 2HG concentration. b, 1 H-NMR analysis for 2HG from CD8 + T lymphocytes cultured as in Fig. 2b . c, Deletion efficiency of Hif1a or Hif2a in CD8 + T lymphocytes, isolated from Hif1a fl/fl dLck cre or Hif2a fl/fl dLck cre mice (n = 4 mice). d, e, Total 2HG levels, normalized to viable cell count or protein content, in Hif1a fl/fl and Hif1a fl/fl dLck cre (d) and Hif2a fl/fl and Hif2a fl/fl dLck cre (e) CD8 + T lymphocytes cultured as in Fig. 2b (n = 4 mice per genotype) . f, Illustration outlining the workflow for metabolite extraction, deletion efficiency and viability experiments in Hif1a fl/fl , Hif1a fl/fl dLck cre , Hif2a fl/fl and Hif2a fl/fl dLck cre CD8 + T lymphocytes. Also shown are viability measurements at day 4 (n = 4 mice per genotype). g, Total amount of 2HG in Hif1a fl/fl (n = 6) and Hif1a fl/fl dLck cre (n = 7) CD8 + T lymphocytes, at indicated times following activation (n ≥ 4 mice per time point). h, Heat map indicating qPCR measurement of expression of enzymes involved in central carbon metabolism in CD8 + T lymphocytes cultured as in Fig. 2b (n = 4 mice per condition). i, Liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantification of total intracellular succinate, fumarate and malate levels in CD8 + T lymphocytes isolated from C57BL/6J mice and cultured as in Fig. 2b (n = 7 mice) . j, Heat map indicating qPCR measurement, in Hif1a fl/fl (n = 4) and Hif1a fl/fl dLck cre (n = 3) CD8 + T lymphocytes growing in 1% oxygen, of expression of enzymes implicated in the hypoxic production of S-2HG. k, qPCR validation of shRNA-knockdowns in CD8 + T lymphocytes isolated from C57BL/6J mice. l-n, LC-MS/MS quantification of S-and R-2HG in CD8 + T lymphocytes isolated from C57BL/6J mice, with shRNA-mediated knockdown of Mdh1 (l), Mdh2 (m) and Ldha (n) (n = 4 pools of 4 mice per pool). o, Validation of Pdk1-Flag and Ldha-Flag expression in Hif1a fl/fl dLck cre CD8 + T lymphocytes by immunoblot analysis for Flag. p, LC-MS/MS quantification of total intracellular glutamate levels in CD8 + T lymphocytes cultured as in Fig. 2b ; n = 7 mice. q, r, LC-MS/MS quantification of total intracellular glutamate levels in Hif1a fl/fl , Hif1a fl/fl dLck cre , Hif2a fl/fl and Hif2a fl/fl dLck cre CD8 + T lymphocytes cultured as in Fig. 2b ; n = 4 mice per genotype. s, Immunoblot of cytosolic fractions for phospho-Pdh-E1α (S232) and total Pdh-E1α in CD8 + T lymphocytes cultured in 1% oxygen in the presence of the indicated concentration of DCA for 48h. t-v, Total intracellular concentration of 2HG (t), 2HG normalized to viable cell count or protein content (u) and glutamate (v) in CD8 + T lymphocytes from C57BL/6J mice cultured as in Fig. 2b and treated with 5mM DCA for the latter 48 h of culture (n = 4 mice). Two-way ANOVA for grouped data (d-f, q, r, t-v) . Paired t-test for matched comparisons (i, p), one-way ANOVA for multiple matched comparisons (g, l-n). Error bars denote s.d. and each dot represents an individual mouse in g, i and p. NS, non-significant, *P < 0.05, **P < 0.01, ***P < 0.0001. Experiments were performed with indicated numbers of mice from multiple occasions. For immunoblot source images, see Supplementary Fig. 1 . Fig. 4f . c, Representative flow cytometry plots of recalling CD45.1 + CD8 + T lymphocytes in indicated organs on day 7 after vaccination (day 37 after transfer).
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Extended Data Figure 9 | S-2HG induces global histone H3 methylation changes in CD8 + T lymphocytes. a, Immunoblot analysis on nuclear extracts for histone H3 methylation marks in activated CD8 + T lymphocytes treated with the indicated doses of S-2HG for 7 days. b, Representative flow cytometry histograms of H3K27me3 staining as a function of increasing S-2HG-octyl ester concentration. c, H3K27me3 staining in CD8 + T lymphocytes treated with or without 500 μM S-2HGoctyl ester and stained with or without fluorophore-conjugated C36B11 antibody. d, qPCR measurement for expression of Utx in unstimulated and stimulated CD8 + T lymphocytes; n = 4 mice. Expression for Utx is displayed for each mouse individually. e, Representative flow cytometry plots of CD44 versus CD62L expression, with associated statistics, on activated CD8 + T lymphocytes after 4 days of treatment with 500 μM S-2HG-octyl ester or 1 μM GSKJ4. Gated on live, CD8 + cells. n = 3 mice. f, Representative flow cytometry plots of CD44 versus CD62L expression on CD8 + T lymphocytes with shRNA-mediated knockdown of Utx, 7 days after transduction. Gated on live CD8 + GFP + cells. Graph on right shows knockdown hairpin fidelity for Utx. g, IgG control ChIP-qPCR for H3K4me3, H3K27me and RNA Pol II at and around the TSS for CD62L, in freshly isolated naive or activated CD8 + T lymphocytes treated with or without 500 μM S-2HG-octyl ester for 7 days. Each profile shows the fold change over the non-binding control primer. Each dot represents an individual primer pair. A pool of n = 6 mice was used for each condition and error bars denote s.e.m. One-way ANOVA for multiple matched comparisons (e). Each dot in e represents an individual mouse. Error bars (e, f) denote s.d. **P < 0.01. Experiments were performed with indicated numbers of mice from at least two occasions. For immunoblot source images, see Supplementary Fig. 1 . 
